Partnering

At Stallergenes Greer, partnerships and open innovation are central to advancing the understanding and treatment of allergic diseases.

For over a century, Stallergenes Greer has been committed to discovering, developing, and delivering innovative allergen immunotherapy (AIT) diagnostics and treatments to improve the quality of life of people living with allergies. 

Building on this legacy, the Group leverages open innovation and cutting-edge technologies to advance understanding of the pathophysiology of allergic diseases and immune responses to AIT.

We collaborate with leading academic and clinical institutions and are advancing AI-driven biomarker discovery to deepen insights into disease mechanisms and support more informed decision-making. Through this integrative approach, we enhance disease characterisation, enable earlier detection, and improve therapeutic strategies, paving the way for more precise and personalised care for patients with allergies.